低剖面覆膜支架治疗肾下腹主动脉瘤的多中心注册长期结果
本研究基于九中心注册数据,回顾性分析619例择期植入低剖面覆膜支架(≤16 Fr)的肾下腹主动脉瘤患者,平均随访56.8个月。8年总体原发临床成功率为72.1%,继发临床成功率93.8%,动脉瘤相关死亡免除率94.4%,再干预免除率74%。结论认为低剖面支架长期结果可接受,但需长期监测和必要时再干预。
要点
- 低剖面支架8年原发临床成功率72.1%,继发成功率93.8%。
- 8年动脉瘤相关死亡免除率94.4%,再干预免除率74%。
- Zenith LP与更差的初级临床成功相关,髂动脉扭曲是预测因素。
核心结论
- 低剖面覆膜支架具有可接受的长期结果,总体生存和动脉瘤相关死亡与传统装置报道一致。
- 长期监测和必要时再干预仍是保证耐久性的关键。
研究设计与样本
- 多中心回顾性注册研究,纳入九中心619例择期植入低剖面覆膜支架(≤16 Fr)的肾下腹主动脉瘤患者。
- 装置包括Ovation(n=373)、Incraft(n=111)和Zenith LP(n=135),平均随访56.8±22.8个月。
主要发现
- 8年总体原发临床成功率为72.1%,继发临床成功率为93.8%。
- 8年总体生存率为53.2%,动脉瘤相关死亡免除率为94.4%,再干预免除率为74%。
- 8年I/III型内漏免除率为86.9%,肢体通畅率为90.4%。
- Zenith LP的原发临床成功显著更差,与更多肢体相关事件有关。
- 不同装置间动脉瘤相关死亡、开放转换、瘤囊增大和I/III型内漏无差异(P = .26)。
关键数值与推荐
- 多因素分析显示髂动脉扭曲(风险比2.053)和Zenith LP(风险比3.818)是临床失败和再干预的显著独立预测因素。
临床怎么用
- 低剖面支架可用于肾下腹主动脉瘤的血管内修复,但需长期监测。
- 对于髂动脉扭曲或使用Zenith LP的患者,应警惕临床失败和再干预风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In recent years, manufacturers have developed new stent grafts with lower profiles to increase the endovascular aneurysm repair applicability. As reported by the current European Society for Vascular Surgery guidelines, long-term evaluation of such low-profile platforms is strongly recommended. This study aims to report outcomes beyond 5 years from a multicenter registry, including a real-world cohort of patients electively treated with low-profile stent grafts. METHODS: A retrospective data collection of patients who had undergone elective implantation of low-profile endograft ≤16 Fr. (Zenith LP, Ovation, Incraft) was performed in nine centers. The primary endpoint was a long-term primary clinical success. Secondary endpoints were survival rate, freedom from abdominal aortic aneurysm (AAA)-related death, freedom from type I to III endoleak, limb patency, and freedom from all reinterventions. The Kaplan-Meier curves were stratified for investigative devices. A multivariate analysis evaluated predictors of primary clinical success and reintervention rate. RESULTS: A total of 619 patients were enrolled (Ovation, n = 373; Incraft, n = 111; and Zenith LP, n = 135), with a mean follow-up of 56.8 ± 22.8 months. The overall primary and the secondary clinical success rate at 8 years was 72.1% and 93.8%, respectively. At 8 years, overall survival was 53.2%, freedom from AAA-related death was 94.4%, freedom from reintervention was 74%, freedom from type I/III endoleak was 86.9%, and limb patency was 90.4%. A significantly worse primary clinical success of the Zenith LP was recorded as dependent on more limb-related events. No differences between platforms were registered in the rate of AAA-related deaths, open conversion, sac enlargement, and type I/III endoleaks (P = .26). Multivariate analysis identified iliac tortuosity (hazard ratio, 2.053) and Zenith LP (hazard ratio, 3.818) as significant independent predictors of clinical failure and reintervention. CONCLUSIONS: Low-profile stent grafts have acceptable long-term outcomes. Overall survival and AAA-related death were in line with those reported for traditional devices. Long-term surveillance and reintervention, when necessary, remain crucial to guarantee durability.
引用
- de Donato G, Pasqui E, Nano G, et al. Long-term results of treatment of infrarenal aortic aneurysms with low-profile stent grafts in a multicenter registry. J Vasc Surg. 2021. PMID: 34634415. doi:10.1016/j.jvs.2021.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。